Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise"

On September 27, the "STAR Summit" was grandly held in Shanghai. The Summit announced the selection list for the fourth anniversary of science and technology innovation.

Shanghai Medicilon Inc (Medicilon) has been selected as a " 2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise" based on its hard-core advantages in biopharmaceutical technology innovation over the years.

Technological innovation is the key to winning the future, and it is also what Medicilon is committed to pursuing. Over the past 19 years, Medicilon has continued to increase investment in research and development, focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA vaccines, PROTAC, ADC, bi/multi-specific antibodies and established an innovative service platform to help promote the "hard core" of drugs. In order to deepen the collaboration between the industry, academia and research institutions, Medicilon also established Medicilon Academician Innovation and Maturity Center, successfully signed the school-enterprise strategic collaboration with China Pharmaceutical University, and reached strategic collaboration with AI pharmaceutical companies such as Insilico Medicine and MindRank to assist the "hard-core" transformation of scientific and technological achievements. In addition, Medicilon also strengthened the construction of scientific and technological innovation talent teams, deepen the reform of talent development systems and mechanisms, support young people to take up the leading role in scientific and technological innovation, and help the "hard-core" growth of talents.

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

阅读全文

What is Toxicokinetics?

Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms toxicokinetics , pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...

阅读全文

Shanghai Medicilon Inc.

搜索此博客